Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.

Abstract

Recent years have witnessed notable advances in the management of intermediate and advanced hepatocellular carcinoma (HCC). However, several questions remain unanswered, including the timely transition from locoregional to systemic therapies and the lack of data on sequencing. In this Commentary, we critically discuss the results of the interesting meta-analysis conducted by Jiang and colleagues on the role of the combination therapy of trans-arterial chemoembolization (TACE) and sorafenib in this setting.